Back

Cost-effectiveness of semaglutide for secondary prevention of cardiovascular disease in the United States

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Disparities: insights into socioeconomic factors and cardiovascular health Health Economics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Susan Hennessy

University of California at San Francisco, San Francisco (United States of America)

4 More presentations in this session

Presentation thumbnail
Cost differences between oral anticoagulation therapies in atrial fibrillation patients
Mr O. Lehtonen (Kuopio, FI)
Abstract Slides Video
Presentation thumbnail
Disparities by region, age, and sex in cardiovascular disease burden attributable to high fasting plasma glucose in China, 2010-2018: a nationwide, population-based study.
Miss X. Cao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Embedding a text message recall system to increase the uptake of cardiovascular screening in Australian general practice. Results of the Text to Detect randomised controlled trial
Miss N. Raffoul (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Independent associations of educational attainment and its joint associations with LE8 score for risk of cardiovascular disease incidence and mortality among Chinese people
Doctor Z. Chen (Changsha, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Disparities: insights into socioeconomic factors and cardiovascular health
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Real-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study
thumbnail
Congress Presentation
The cost-effectiveness of a digitally enabled telerehabilitation program delivered nationally to patients in Australia
thumbnail
Congress Presentation
Let’s go digital: implementing cardiac rehabilitation - discussion

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources